Skip to content

REGEN BIOPHARMA, INC.: 10-Q filed 2015-07-29

What REGEN BIOPHARMA, INC. reported in its quarterly report filed 2015-07-29 (fiscal Q3 2015): 22 published measures, 57 facts as tagged in accession 0001607062-15-000336.

This filing

Form
10-Q (quarterly report)
Filed
2015-07-29
Fiscal period
fiscal Q3 2015
Accession
0001607062-15-000336 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All REGEN BIOPHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2015-06-30228,003USD
At 2014-09-3010,655USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2015-06-30145,281USD
At 2014-09-30140,286USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2015-06-3082,722USD
At 2014-09-30-129,631USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-09-30115,922USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2015-04-01 to 2015-06-30-1,562,371USD91
2014-10-01 to 2015-06-30-10,594,463USD273
2012-04-24 to 2015-06-30-11,873,041USD1163
2014-04-01 to 2014-06-30-166,021USD91
2013-10-01 to 2014-06-30-561,751USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2015-04-01 to 2015-06-300USD91
2014-10-01 to 2015-06-300USD273
2014-04-01 to 2014-06-300USD91
2013-10-01 to 2014-06-300USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2014-10-01 to 2015-06-3010,559,316USD273
2013-10-01 to 2014-06-30490,000USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2015-06-30-11,873,041USD
At 2014-09-30-1,278,577USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2015-04-01 to 2015-06-30110,648,054shares91
2014-10-01 to 2015-06-3079,454,728shares273
2014-04-01 to 2014-06-3051,909,907shares91
2013-10-01 to 2014-06-3037,082,956shares273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2015-04-01 to 2015-06-30-621,410USD91
2014-10-01 to 2015-06-30-1,456,238USD273
2014-04-01 to 2014-06-30-157,867USD91
2013-10-01 to 2014-06-30-513,745USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2015-06-30228,003USD
At 2014-09-3010,655USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2015-04-01 to 2015-06-303,512USD91
2014-10-01 to 2015-06-3018,742USD273
2014-04-01 to 2014-06-300USD91
2013-10-01 to 2014-06-300USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2015-06-30145,281USD
At 2014-09-30140,286USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2015-06-301,190USD
At 2014-09-303,305USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2015-04-01 to 2015-06-3068,081USD91
2014-10-01 to 2015-06-3093,287USD273
2014-04-01 to 2014-06-300USD91
2013-10-01 to 2014-06-3013,867USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2015-06-30109,310,811shares
At 2014-09-3051,907,917shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2015-06-3011,209,694USD
At 2014-09-30485,097USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2015-06-300USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2014-10-01 to 2015-06-30-10,594,463USD273
2013-10-01 to 2014-06-30-561,751USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2015-04-01 to 2015-06-30463,765USD91
2014-10-01 to 2015-06-30906,754USD273
2014-04-01 to 2014-06-30127,580USD91
2013-10-01 to 2014-06-30389,961USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2014-10-01 to 2015-06-300USD273
2013-10-01 to 2014-06-30300,000USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2014-10-01 to 2015-06-30-2,115USD273
2013-10-01 to 2014-06-30117USD273

Inspect the source

Entity
REGEN BIOPHARMA, INC. / CIK 0001589150
Captured
2026-09-20T09:23:48.532Z
SEC response SHA-256
0bbe246b6080c7701ba978807745a4ba9de62971ab4db32e8d3e2fa2c4f26a87

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001589150.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))